Printer Friendly

TSI COMPLETES ACQUISITION OF HSRI

 TSI COMPLETES ACQUISITION OF HSRI
 WORCESTER, Mass., June 30 /PRNewswire/ -- TSI Corporation


(NASDAQ: TSIN) announced today that it completed the acquisition of Health and Sciences Research Incorporated for $6 million in cash. The company had previously announced on June 19 the signing of a definitive agreement to buy HSRI, an established supplier of clinical testing services to major pharmaceutical and biotechnology companies.
 TSI is a life sciences company offering in vitro and in vivo preclinical and toxicology testing services, human clinical testing services, and diagnostic intermediate products. TSI is also developing advanced toxicology tests and disease models based on genetic engineering and transgenic techniques to improve the efficiency of the pharmaceutical/chemical development process.
 -0- 6/30/92
 /CONTACT: Munro W. Pitt, senior vice president of TSI Corporation, 508-755-0550, or Peter Feinstein of Feinstein Partners, 617-577-8110, for TSI/
 (TSIN) CO: TSI Corporation; Health and Sciences Research Inc.99 ST: Massachusetts IN: MTC SU:


TM -- NE005 -- 5169 06/30/92 12:21 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:162
Previous Article:IBAA/STATE GROUPS LAUNCH GRASSROOTS CAMPAIGN TO FIGHT REGULATORY BURDEN
Next Article:CHEVRON ANNOUNCES FIRST OIL EXPORTED FROM PAPUA NEW GUINEA
Topics:


Related Articles
TSI ANNOUNCES Q2 OUTLOOK AND MANAGEMENT APPOINTMENTS
TSI CORPORATION REPORTS RECORD FIRST HALF AND SECOND QUARTER REVENUES
TSI CORPORATION ANNOUNCES PROPOSED ACQUISITION OF GERMAN PRECLINICAL TESTING FACILITY
TSI CORPORATION REPORTS NINE-MONTH AND THIRD QUARTER RESULTS
TSI CORPORATION ACQUIRES GERMAN PRECLINICAL TESTING FACILITY
TSI CORPORATION TO ACQUIRE CLINICAL RESEARCH GROUP
TSI CORP. ANNOUNCES RESTRUCTURING AND FORECASTS YEAR-END RESULTS
TSI CORPORATION FORECASTS THIRD QUARTER RESULTS AND INTENSIFIES FISCAL 1993 COST REDUCTION PROGRAM
GENZYME TRANSGENICS TO ACQUIRE BIODEVELOPMENT LABORATORIES
GENZYME TRANSGENICS TO SELL GDRU FOR $9.5 MILLION, COMPLETES RESTRUCTURING OF TSI TESTING BUSINESS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters